An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

Overweight patients given an experimental weight loss drug being developed by China's Sciwind Biosciences lost an average of ...

Novo Nordisk announced in June that its weight-loss drug Wegovy received similar approval in China. Eli Lilly and Co. (LLY) announced on its WeChat account Friday that it has won approval from ...

also approved in China, and weight-loss drug Zepbound. Eli Lilly and Novo Nordisk are racing to increase production in a weight-loss market estimated to reach at least $100 billion globally by the ...

Eli Lilly & Co.’s Mounjaro ... s most severely hit by obesity. China’s National Medical Products Administration approved Lilly’s shot for long-term weight management on Friday, the company ...

The Chinese drug regulator, the National Medical Products Administration (NMPA), has approved Eli Lilly’s (NYSE ... initial sales of its weight loss drug, Wegovy, in China to avoid supply ...

On Friday, China’s National Medical Products Administration (NMPA) approved Eli Lilly And Co (NYSE ... Mounjaro for diabetes and Zepbound for weight loss. Related: Chinese Generic Ozempic ...

The global market for diabetes drugs used for treating obesity is expected to expand in Asia, as new players jostle with giants Eli Lilly and ... The market for weight-loss drugs could see new ...

The two-year shortage of Eli ... t yet clear. Many patients still report difficulty getting the drugs despite Lilly saying there’s enough. Pharmacies that make copies of the weight-loss and ...